Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | CA12 | O43570 | 16/20 | 0.56 |
| ▸ | CA1 | P00915 | 16/20 | 0.56 |
| ▸ | CA2 | P00918 | 16/20 | 0.56 |
| ▸ | CA9 | Q16790 | 16/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7563850 | 0.81 | PIP4K2A (0.45) | KMT2AMEN1 | |
| SCHEMBL8210609 | 0.80 | RAB9A (0.50) | KMT2AMEN1PTPN7MAPT | |
| SCHEMBL7518699 | 0.80 | MAOA (0.51) | KMT2ACA12CA1CA2CA9 | |
| SCHEMBL7529461 | 0.80 | KMT2A (0.49) | KMT2ACA12CA1CA2CA9 | |
| SCHEMBL7521962 | 0.80 | ALDH1A1 (0.51) | KMT2ACA12CA1CA2CA9 | |
| SCHEMBL7524755 | 0.80 | SMN1; SMN2 (0.55) | KMT2AMEN1MAPT | |
| SCHEMBL28499329 | 0.79 | KMT2A (1.00) | KMT2ACA12CA1CA2CA9 | |
| SCHEMBL7522234 | 0.76 | KMT2A (0.62) | KMT2ACA12CA1CA2CA9 | |
| SCHEMBL7518438 | 0.74 | EPHX1 (0.61) | KMT2ACA2CA9MEN1CA4 | |
| SCHEMBL6252334 | 0.73 | KMT2A (1.00) | KMT2ACA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020058694-A1 | Ureido and thioureido derivatives of 4-amino-2(5H)-furanones and 4-amino-2(5H)-thiophenones as antitumor agents | ROCHE DIAGNOSTICS GMBH | 2002-05-16 | — | — | US | disclosed |
| US-6333346-B1 | AMINOFURANONEUREAS OR THIOUREAS 4-AMINO-2(5H)-THIOPHENONES AS ANTITUMOR AGENTS | ROCHE DIAGNOSTICS GMBH (DE) | 2001-12-25 | — | — | US | disclosed |
| EP-1009747-A1 | UREIDO AND THIOUREIDO DERIVATIVES OF 4-AMINO-2(5H)-FURANONES AND 4-AMINO-2(5H)-THIOPHENONES AS ANTITUMOR AGENTS | Roche Diagnostics GmbH (DE) | 2000-06-21 | — | — | EP | disclosed |
| WO-1999012917-A1 | UREIDO AND THIOUREIDO DERIVATIVES OF 4-AMINO-2(5H)-FURANONES AND 4-AMINO-2(5H)-THIOPHENONES AS ANTITUMOR AGENTS | ROCHE DIAGNOSTICS GMBH (DE) | 1999-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058694-A1 | Ureido and thioureido derivatives of 4-amino-2(5H)-furanones and 4-amino-2(5H)-thiophenones as antitumor agents | UTS2R, SRD5A2, SRD5A1 | KMT2A 3288/4885CA12 3070/4885CA1 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.